Sodium-Glucose Transporter 2 Inhibitors [glifloziny]

topical
783
Terms

gliflozin
inhibitory SGLT2
inhibitory transportéru 2 pro sodík a glukózu

 

Gliflozin
Gliflozins
SGLT-2 Inhibitor
SGLT-2 Inhibitors
SGLT2 Inhibitor
SGLT2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitor

Persistent link   https://www.medvik.cz/link/D000077203
Definition

Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS.

DUI
D000077203 MeSH Browser
CUI
M000639744
History note
2019
Public note
2019

Allowable subheadings

AD
administration & dosage 107
AE
adverse effects 59
AN
analysis 1
BL
blood 1
CF
cerebrospinal fluid
CS
chemical synthesis
CH
chemistry 3
CL
classification 10
EC
economics 16
HI
history 1
IM
immunology
IP
isolation & purification
ME
metabolism 5
PK
pharmacokinetics 15
PD
pharmacology 242
PO
poisoning
RE
radiation effects
ST
standards
SD
supply & distribution
TU
therapeutic use 410
TO
toxicity
UR
urine

D Chemicals and Drugs
D27 Chemical Actions and Uses 374
D27.505 Pharmacologic Actions 408
D27.505.519 Molecular Mechanisms of Pharmacological Action 89
D27.505.519.124 Alkylating Agents 91
D27.505.519.143 Amylin Receptor Agonists
D27.505.519.162 Angiotensin Receptor Antagonists 222
D27.505.519.170 Antacids 162
D27.505.519.174 Antidiuretic Hormone Receptor Antagonists 28
D27.505.519.178 Antifoaming Agents 12
D27.505.519.182 Antiglycation Agents
D27.505.519.186 Antimetabolites 120
D27.505.519.217 Antioxidants 2 520
D27.505.519.241 Aversive Agents
D27.505.519.265 Bradykinin Receptor Antagonists 10
D27.505.519.270 Calcitonin Gene-Related Peptide Receptor Antagonists 72
D27.505.519.275 CCR5 Receptor Antagonists 4
D27.505.519.295 Cerumenolytic Agents 1
D27.505.519.334 Cystine Depleting Agents
D27.505.519.349 Cytochrome P-450 Enzyme Inducers 10
D27.505.519.364 Endothelin Receptor Antagonists 119
D27.505.519.374 Enzyme Activators 30
D27.505.519.389 Enzyme Inhibitors 873
D27.505.519.405 Enzyme Reactivators 16
D27.505.519.421 Fibrin Modulating Agents 2
D27.505.519.452 Heparin Antagonists 23
D27.505.519.507 Immune Checkpoint Inhibitors 328
D27.505.519.562 Membrane Transport Modulators 22
D27.505.519.593 Mitosis Modulators 3
D27.505.519.625 Neurotransmitter Agents 517
D27.505.519.656 Nitric Oxide Donors 63
D27.505.519.828 Peptidomimetics 11
D27.505.519.871 Radiopharmaceuticals 806
D27.505.519.914 Sequestering Agents 1
D27.505.519.936 Sodium-Glucose Transporter 2 Inhibitors 783
D27.505.519.947 Sphingosine 1 Phosphate Receptor Modulators 25
D27.505.519.952 Toll-Like Receptor Agonists
D27.505.519.957 Viral Fusion Protein Inhibitors
D27.505.696 Physiological Effects of Drugs 52
D27.505.696.422 Hypoglycemic Agents 2 721
D27.505.696.422.125 Glucagon-Like Peptide-1 Receptor Agonists 31
D27.505.696.422.249 Glycoside Hydrolase Inhibitors 47
D27.505.696.422.374 Amylin Receptor Agonists
D27.505.696.422.500 Dipeptidyl-Peptidase IV Inhibitors 573
D27.505.696.422.625 Insulin Secretagogues
D27.505.696.422.688 PPAR-gamma Agonists
D27.505.696.422.750 Sodium-Glucose Transporter 2 Inhibitors 783

Add